Erin J. Howell

Erin J. Howell

Senior Associate
New York

Email erin.howell@​hoganlovells.com

Phone +1 212 918 3634

Fax +1 212 918 3100

Practice groupCorporate

Erin Howell knows that a valuable adviser needs both breadth and depth of knowledge. That's her key to advising clients across a broad range of industries on their most important corporate transactions, while maintaining a particular focus on key industries. From life sciences to life insurance, Erin has counseled clients on a variety of business, corporate, and regulatory matters.

Erin focuses on U.S. and international mergers and acquisitions, internal reorganizations, and asset purchase and sale transactions – including pharmaceutical products and blocks of insurance business. Erin has represented clients in industries as varied as financial services, pharmaceuticals and life sciences, textiles, transportation, and health services. Within the insurance industry, she brings a decade of experience dealing with complex reinsurance, transactional, and regulatory matters, including M&A, renewal rights, shell acquisitions, and regulatory issues for insurance underwriters, producers, and reinsurers.

Awards and recognitions

2010

Legal Aid Society Recognition Award

Education and admissions

Education

J.D., 2008

B.A., Michigan State University, summa cum laude, 2003

Bar admissions and qualifications

New York

Representative experience

Medicines Development for Global Health on the sale of its Priority Review Voucher.

Novartis in connection with a strategic collaboration with Cellular Biomedicine Group, Inc. to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.

Novartis on its licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates.

Celgene on the entry into a strategic collaboration and licensing agreement with Kyn Therapeutics with an $80 million upfront payment.

Helsinn Healthcare SA in connection with the acquisition of the worldwide rights to Valchlor©/Ledaga© from Actelion Pharmaceuticals, Ltd.

Kiadis, a clinical stage biopharmaceutical company, on its acquisition of US-based CytoSen Therapeutics, Inc.

Elastagen Pty Ltd in relation to its sale to Allergan plc for up to US$260m.

A leading global life sciences company on its minority investment in a clinical lab, with an option to acquire.

Loading data